Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
Open Access
- 20 June 2023
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 12 (6) , 1313
Abstract
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the patients still develop resistance within the first year of therapy. Therefore, understanding the mechanisms of BRAFi/MEKi-acquired resistance has become a priority for researchers. Among others, oxidative stress-related mechanisms have emerged as a major force. The aim of this study was to evaluate the contribution of Nrf2, the master regulator of the cytoprotective and antioxidant response, in the BRAFi/MEKi acquired resistance of melanoma. Moreover, we investigated the mechanisms of its activity regulation and the possible cooperation with the oncogene YAP, which is also involved in chemoresistance. Taking advantage of established in vitro melanoma models resistant to BRAFi, MEKi, or dual resistance to BRAFi/MEKi, we demonstrated that Nrf2 was upregulated in melanoma cells resistant to targeted therapy at the post-translational level and that the deubiquitinase DUB3 participated in the control of the Nrf2 protein stability. Furthermore, we found that Nrf2 controlled the expression of YAP. Importantly, the inhibition of Nrf2, directly or through inhibition of DUB3, reverted the resistance to targeted therapies.Keywords
Funding Information
- University of Turin, Department of Clinical and Biological Sciences (local funds to A.R. and S.P., local funds to C.D.)
- Department of Sciences and Pharmaceutical Technology (local funds to A.R. and S.P., local funds to C.D.)
This publication has 73 references indexed in Scilit:
- A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress responseNature Communications, 2014
- Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITFCancer Cell, 2013
- YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genesOncogene, 2012
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesisNature, 2011
- The cytoprotective role of the Keap1–Nrf2 pathwayArchives of Toxicology, 2011
- Breaking the chains: structure and function of the deubiquitinasesNature Reviews Molecular Cell Biology, 2009
- Anchorage-independent cell growth signature identifies tumors with metastatic potentialOncogene, 2009
- Tobacco Smoke: Involvement of Reactive Oxygen Species and Stable Free Radicals in Mechanisms of Oxidative Damage, Carcinogenesis and Synergistic Effects with Other Respirable ParticlesInternational Journal of Environmental Research and Public Health, 2009
- TEAD mediates YAP-dependent gene induction and growth controlGenes & Development, 2008
- Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccineInternational Journal of Cancer, 2005